Reverse Convertible with Autocall on Fresenius Medical Care
The Bavarian medical technology provider plays a leading role in the globally growing dialysis market. Here, the FMC testing of dialysis machines takes place at the Schweinfurt plant. FRESENIUS
Our latest investment idea, with a term of 18 months and a coupon of four percent, offers attractive returns with a manageable investment horizon. Fresenius Medical Care from Bavaria is one of the leading specialists in dialysis. Following its low at the end of 2018, the share price has recently corrected.
In a period of sideways-trending equity markets, classic equity bonds with express provide attractive yields with a manageable investment horizon. In addition, classic reverse convertible bonds offer real downward protection. With our structure, from the 6th month onwards there is a quarterly chance of early redemption through a falling redemption barrier.
Fresenius Medical Care AG Co KGaA is a leading global provider of dialysis products and services for the medical care of people with chronic and acute kidney failure. The company supports the two main treatment methods, hemodialysis and peritoneal dialysis. Fresenius Medical Care AG Co KgaA is recommended to buy or hold in 27 out of 27 available analyst estimates (source: Bloomberg). Should a delivery of shares take place at the end of the term, the shares would be delivered at a discount of 20% to the starting level.
Share price Fresenius Medical Care AG in Euro 5 years
How the reverse convertible bond with Express works
The reverse convertible express on Fresenius Medical Care AG Co KGaA is a bearer bond of BNP Paribas Emissions- und Handelsgesellschaft mbH, Frankfurt am Main, with a term until August 28, 2020 at the latest, except for an early redemption.
Payment of interest
A guaranteed interest rate of EUR 10.00 (4.00% p.a.) will be paid quarterly until premature repayment, at most until final maturity.
On the respective observation day, it is examined whether the Fresenius Medical Care AG Co KGaA share is at or above the corresponding repayment barrier. If this is the case, the certificate is repaid early at par value. Otherwise, the certificate will continue until the next observation day.
End of term
A final fixation will be performed to determine whether the Fresenius Medical Care AG Co KGaA share is quoted above the strike price of 80% of the initial fixation. If this is the case, the nominal amount will be paid per certificate, otherwise the physical delivery of the Fresenius Medical Care AG Co KGaA share will take place at the subscription ratio (cash settlement for fractions).
Reverse Convertible with Autocall
|Underlying||Fresenius Medical Care AG Co KGaA|
|Issuer||BNP Paribas Emissions- und Handelsgesellschaft mbH, Frankfurt am Main|
|Issue price||EUR 1000,-|
|Subscription period||Until 21th of February 2019, early closing possible|
|Expresslevel||After 6 months = 100% / afterwards quarterly 3% falling|
Your contact person
CEO Picard Angst MEA
This content is for information purposes only and should not be construed as an investment recommendation, investment advice or the result of any financial analysis, nor should it be construed as an offer or invitation to submit an offer. The "Guidelines for Ensuring the Independence of Financial Research" of the Swiss Bankers Association do not apply to this publication. This document does not constitute a simplified prospectus pursuant to Art. 5 CISA, an offering prospectus pursuant to Art. 652a or Art. 1156 CO or a listing notice within the meaning of the Listing Rules. Therefore, only the simplified prospectus drawn up by the issuer is authoritative, together with all additional product information of the issuer. The simplified prospectus and the additional product information of the issuer as well as the brochure "Special Risks in Securities Trading" may be obtained free of charge at any time from Picard Angst AG, CH-8808 Pfäffikon SZ (Tel. +41 (0)55 290 55 55* or e-mail email@example.com).
From a legal point of view, structured products are debt securities (receivables), so that the default risk depends on the creditworthiness of the issuer. In this respect, the investor bears the risk of a deterioration in the creditworthiness or insolvency of the issuer, which can lead to a partial or total loss of the invested capital.
For a detailed description of all material risks (issuer risk, market risk, currency risk, liquidity risk, product-specific risks, etc.), please refer explicitly to the simplified prospectus of the issuer, together with all additional product information of the issuer. The information contained herein does not replace the qualified advice absolutely necessary prior to any purchase or investment decision, in particular with regard to all associated risks and the suitability of this product.
This publication and the financial product depicted therein are not intended for persons subject to a jurisdiction that restricts or prohibits the distribution of this financial product or of this publication or the information contained therein.
Performance achieved in the past must never be understood as an indication or guarantee of future performance. All information is provided without guarantee.
Calls to the number marked with (*) may be recorded. If you call this number, we assume that you agree to this business practice.
04.02.2019 © Picard Angst AG. All rights reserved.